文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

重症COVID-19 ARDS需ECMO支持患者的呼吸机相关性肺炎复发

Recurrent ventilator-associated pneumonia in severe Covid-19 ARDS patients requiring ECMO support.
PubMed 文献 · Ann Intensive Care · 2024-04-25
一句话结论需ECMO的重症COVID-19 ARDS患者首次VAP后复发率82%,首次VAP抗菌治疗≥8天与<8天相比未降低复发风险。

该回顾性研究纳入2020年3月至2022年1月因COVID-19重症肺炎接受ECMO的成人患者252例,其中226例(90%)发生首次VAP,排除16例肺脓肿后210例纳入分析。172例(82%)发生VAP复发,首次VAP至复发的中位时间10(7-13)天;首次VAP以肠杆菌科(52%)和铜绿假单胞菌(28%)为主,首次复发以肠杆菌科(62%)和铜绿假单胞菌(51%)为主。158例(75%)接受短疗程抗菌治疗(<8天,中位6(5-7)天),52例(25%)接受长疗程(≥8天,中位9(8-10)天),以死亡和拔管为竞争风险估计的VAP复发累积发生率在两组间无差异。

要点

  • 210例首次VAP患者中172例(82%)发生VAP复发,首次VAP至复发中位时间10(7-13)天。
  • 首次VAP病原以肠杆菌科52%、铜绿假单胞菌28%为主;首次复发以肠杆菌科62%、铜绿假单胞菌51%为主。
  • 首次VAP接受≥8天抗菌治疗(52例,中位9(8-10)天)与<8天(158例,中位6(5-7)天)相比,以死亡和拔管为竞争风险的VAP复发累积发生率无差异。
  • 研究纳入2020年3月至2022年1月因COVID-19重症肺炎接受ECMO的成人患者,252例中226例(90%)发生首次VAP。

适用人群与场景

  • 2020年3月至2022年1月因COVID-19重症肺炎接受ECMO支持的成人患者,回顾性纳入。
  • 252例纳入患者中226例(90%)发生首次VAP,排除16例肺脓肿后210例纳入VAP复发分析。

处置流程与药物剂量

  • 首次VAP抗菌治疗:158例(75%)为短疗程(<8天,中位6(5-7)天),52例(25%)为长疗程(≥8天,中位9(8-10)天)。

研究设计与关键结果

  • 回顾性研究纳入252例COVID-19重症肺炎ECMO成人患者,226例(90%)发生首次VAP,排除16例肺脓肿后210例分析。
  • 210例中172例(82%)发生VAP复发,首次VAP至复发中位时间10(7-13)天。
  • 首次VAP病原:铜绿假单胞菌28%、肠杆菌科52%;首次复发:铜绿假单胞菌51%、肠杆菌科62%。
  • 短疗程组158例(75%,<8天,中位6(5-7)天)与长疗程组52例(25%,≥8天,中位9(8-10)天)相比,以死亡和拔管为竞争风险估计的VAP复发累积发生率无差异。

证据类型、等级与局限

  • 证据类型:回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在需ECMO支持的重症COVID-19 ARDS患者中,首次VAP后复发常见(82%),病原以肠杆菌科和铜绿假单胞菌为主。
  • 作者结论:首次VAP抗菌治疗≥8天与较短疗程相比未降低VAP复发风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To describe ventilator-associated pneumonia (VAP) recurrence in COVID-19 patients requiring extracorporeal membrane oxygenation (ECMO) support, and to evaluate the impact of antimicrobial treatment duration of the first VAP episode on VAP recurrence.

METHODS: Adult patients with COVID-19 severe pneumonia on ECMO admitted between March 2020 and January 2022 were retrospectively included. Primary outcome was incidence of VAP recurrence, and secondary outcome was the impact of duration of antimicrobial treatment on VAP recurrence.

RESULTS: Among the 252 included patients, 226 (90%) developed a first VAP. Sixteen had lung abscess and were excluded, leaving 210 patients. VAP recurrence occurred in 172 patients (82%), with a median (IQR) time from first VAP to recurrence of 10 (7-13) days. Pseudomonas aeruginosa and Enterobacteriaceae were respectively responsible for 28% and 52% of first VAP, and 51% and 62% of first recurrence episodes. Among the 210 patients with a first VAP, 158 (75%) received a short course of antibiotics [< 8 days, median (IQR) duration 6 (5-7) days] and 52 (25%) received a prolonged course of antibiotics [≥ 8 days, median (IQR) duration 9 (8-10) days]. Estimated cumulative incidence of VAP recurrence, taking into account death and extubation as competing risks, was not different in patients with short- and prolonged-antimicrobial treatment.

CONCLUSIONS: In patients with severe Covid-19-ARDS requiring ECMO support, VAP recurrence occurs frequently, with Enterobacteriaceae and Pseudomonas aeruginosa as predominant causative microorganisms. An antimicrobial treatment of ≥ 8 days for the treatment of first VAP episode did not reduce the risk of VAP recurrence, as compared to shorter duration.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Collado-Lledó E, Moyon Q, Chommeloux J, et al. Recurrent ventilator-associated pneumonia in severe Covid-19 ARDS patients requiring ECMO support. Ann Intensive Care. 2024. PMID: 38662274. doi:10.1186/s13613-024-01295-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。